Clinical Trial Update: Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluating SGN-40 (dacetuzumab) in patients with relapsed diffuse large B-cell lymphoma and other non-Hodgkin lymphomas, sponsored by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• SGN-40 (dacetuzumab)

Snippet

Sponsor: Seagen Inc. | Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED